Opinion|Videos|August 14, 2024
Comparing Telomerase Inhibitors and EMAs in ESA-Ineligible LR MDS
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series
- Please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the LR-MDS ESA ineligible patient?
Advertisement
Related to this article
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5